Aura Biosciences (AURA) EV/FCF: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:50:39.158Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:50:39.158Z.

Quote observation: 2026-10-06T17:50:08.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 634,261,784
Total debt · period ending 2026-06-30: 16,594,000
Cash · period ending 2026-06-30: 67,836,000
TTM free cash flow · period ending 2026-06-30: -102,653,000

FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

AURA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

AURA Competitors' EV/FCF Ratio

AURA

Aura Biosciences, Inc.

Current

Market Cap

$634.26M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SOPH

SOPHiA GENETICS S.A.

vs AURA

Market Cap

$632.15M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs AURA

Market Cap

$638.60M

EV/FCF Ratio

N/A

TTM Avg

710.97x

3Y Avg

756.83x

5Y Avg

756.83x

PRME

Prime Medicine, Inc.

vs AURA

Market Cap

$628.55M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLYM

Climb Bio, Inc.

vs AURA

Market Cap

$616.72M

EV/FCF Ratio

N/A

TTM Avg

370.81x

3Y Avg

370.81x

5Y Avg

370.81x

STLN

Starling Oncology, Inc.

vs AURA

Market Cap

$657.89M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs AURA

Market Cap

$666.00M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs AURA

Market Cap

$664.82M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs AURA

Market Cap

$667.67M

EV/FCF Ratio

13.14x

TTM Avg

10.66x

3Y Avg

30.61x

5Y Avg

30.61x

IRWD

Ironwood Pharmaceuticals, Inc.

vs AURA

Market Cap

$600.01M

EV/FCF Ratio

4.95x

TTM Avg

12.45x

3Y Avg

11.11x

5Y Avg

9.59x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Aura Biosciences, Inc. (AURA)	$634.26M	N/A	N/A	N/A	N/A
SOPHiA GENETICS S.A. (SOPH)vs ›	$632.15M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$638.60M	N/A	710.97x	756.83x	756.83x
Prime Medicine, Inc. (PRME)vs ›	$628.55M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$616.72M	N/A	370.81x	370.81x	370.81x
Starling Oncology, Inc. (STLN)vs ›	$657.89M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$666.00M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$664.82M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$667.67M	13.14x	10.66x	30.61x	30.61x
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$600.01M	4.95x	12.45x	11.11x	9.59x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

AURA EV/FCF Ratio Metrics

AURA Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics